GlassScriptPhysician profile
Kevin A Rogers
NPI 1760647960
$7,302.31
in general payments reported to CMS, 2019-2025
24 companies · $2,284 in 2025
The $2,284 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $504 · 2021: $790 · 2022: $886 · 2023: $1,157 · 2024: $774 · 2025: $2,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095 · Travel and Lodging: $992 · Entertainment: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.91 |
| Travel and Lodging | $992.00 |
| Entertainment | $128.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $1,081.41 | 2021-2025 | Cirrus Hd-Oct |
| Alcon Vision LLC | $865.17 | 2019-2025 | Tryptyr, Dailies Total1, Precision 1 |
| Coopervision INC. | $861.62 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Optos, INC. | $687.77 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $669.34 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $326.32 | 2022-2025 | Miebo, Infuse, Vyzulta |
| Kala Pharmaceuticals, INC. | $309.92 | 2021-2022 | |
| Dompe US, INC. | $307.96 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $295.55 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $294.41 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $260.79 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $203.51 | 2021-2024 | |
| Astellas Pharma US INC | $201.38 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $144.13 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $142.47 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $122.26 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $117.65 | 2024 | Tecnis Simplicity, Tecnis Iol, Veritas Vision System |
| Allergan, INC. | $113.26 | 2019-2021 | |
| Maculogix, INC. | $89.61 | 2019 | |
| Abbvie INC. | $88.26 | 2022 | |
| Eyevance Pharmaceuticals LLC | $41.85 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Beaver-Visitec International, INC. | $19.91 | 2019-2020 | |
| Harrow Eye, LLC | $18.96 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.